source
- Docket commenters call for flexibility in rare disease trial design and evidence, but question FDA’s RCT focusComments to the US Food and Drug Administration (FDA) public docket on statistical considerations for study designs in rare disease clinical investigations supported the need for flexibility in tri…raps · 1d ago↗ source
- This Week at FDA: Overton nomination pulled, FDA promotes international reliance, and moreWelcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. This wee…raps · 1d ago↗ source
- FDA approves Regeneron's first siRNA therapy for generalized myasthenia gravisThe FDA has granted approval for Regeneron's siRNA drug Livsayis (cemdisiran) for adult patients with generalized myasthenia gravis who are positive for anti‑acetylcholine receptor antibodies. Thi…